Incyte | INCY - Cash And Equivalent


Incyte reported $3.98B in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agenus USD 18.74M 16.26M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Exelixis USD 226.15M 256.34M Mar/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Novartis USD 6.88B 2.68B Mar/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026